(Updates with stock price movement in the headline and first paragraph)
ADC Therapeutics (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026," said Chief Medical Officer Mohamed Zaki in a statement late Monday.
The stock was up 0.8% in recent trading.
Price: 1.91, Change: +0.01, Percent Change: +0.53
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。